We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction
Read MoreHide Full Article
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, recently announced PanDNA, a versatile Nanobind DNA extraction kit.
With the addition of this new offering, the range of sample types appropriate for long-read sequencing is now greater and includes bacteria, cells, tissue, blood, plant nuclei, and insects.
Price Performance
For the past six months, PACB’s shares have plunged 51.8% compared with the industry’s decline of 4.8%. The S&P 500 increased 5.8% in the same time frame.
Image Source: Zacks Investment Research
More on the News
Researchers can effectively extract high-quality, high molecular weight DNA from a variety of sample types with the help of Nanobind kits. These kits are flexible, supporting high-throughput (Nanobind CBB HT kit) and manual (Nanobind PanDNA kit) configurations. Their quick and easy-to-use protocol works with platforms from automation suppliers that are compatible with PacBio.
The existing high-throughput extraction Nanobind HT CBB kit will now support two new sample types — animal blood and bacteria —and can accommodate 96 samples per run.
The new PanDNA kit will be the go-to kit for extracting DNA optimized for HiFi sequencing. PanDNA is likely to support researchers to complete accurate genomen assemblies, identify structural variants, and explore complex biological systems in extraordinary detail using the Revio sequencing system.
The new PanDNA kit is expected to be available for purchase and shipment in February 2024.
Industry Prospects
Per a report by Future Market Insights, the anticipated size of the DNA/RNA extraction market in 2022 was $1.3 billion and is estimated to expand at a CAGR of 7.4% between 2023 and 2033, totaling around $2.6 billion by 2033. The growth of the DNA/RNA extraction market is attributed to its global utilization across the healthcare industry.
The market for global DNA/RNA extraction market has gained importance with the rise in demand for the automation of DNA/RNA extraction technology, new user-friendly and easy extraction kits, and usage of DNA/RNA in the marking of new diseases caused by microorganisms. This is expected to raise the DNA/RNA extraction kit market growth during the forecast period.
Notable Developments
In October 2023, PacBio announced the availability of a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis, the PacBio WGS Variant Pipeline. This availability aims to significantly strengthen PacBio’s global sequencing business.
Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Acadia Healthcare (ACHC - Free Report) , and Universal Health Services (UHS - Free Report) .
Integer Holdings, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integer Holdings’ shares have rallied 43.5% in the past year against the industry’s 3.7% decline.
Acadia Healthcare, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.4%. ACHC’s long-term earnings are expected to grow at 11.2%.
Acadia’s shares have gained 11.7% in the past six months against the industry’s decline of 5%.
Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated growth rate of 4.4% for 2024. UHS’s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 5.47%.
UHS’s shares have gained 1.9% in the past six months against the industry’s 5% decline.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, recently announced PanDNA, a versatile Nanobind DNA extraction kit.
With the addition of this new offering, the range of sample types appropriate for long-read sequencing is now greater and includes bacteria, cells, tissue, blood, plant nuclei, and insects.
Price Performance
For the past six months, PACB’s shares have plunged 51.8% compared with the industry’s decline of 4.8%. The S&P 500 increased 5.8% in the same time frame.
Image Source: Zacks Investment Research
More on the News
Researchers can effectively extract high-quality, high molecular weight DNA from a variety of sample types with the help of Nanobind kits. These kits are flexible, supporting high-throughput (Nanobind CBB HT kit) and manual (Nanobind PanDNA kit) configurations. Their quick and easy-to-use protocol works with platforms from automation suppliers that are compatible with PacBio.
The existing high-throughput extraction Nanobind HT CBB kit will now support two new sample types — animal blood and bacteria —and can accommodate 96 samples per run.
The new PanDNA kit will be the go-to kit for extracting DNA optimized for HiFi sequencing. PanDNA is likely to support researchers to complete accurate genomen assemblies, identify structural variants, and explore complex biological systems in extraordinary detail using the Revio sequencing system.
The new PanDNA kit is expected to be available for purchase and shipment in February 2024.
Industry Prospects
Per a report by Future Market Insights, the anticipated size of the DNA/RNA extraction market in 2022 was $1.3 billion and is estimated to expand at a CAGR of 7.4% between 2023 and 2033, totaling around $2.6 billion by 2033. The growth of the DNA/RNA extraction market is attributed to its global utilization across the healthcare industry.
The market for global DNA/RNA extraction market has gained importance with the rise in demand for the automation of DNA/RNA extraction technology, new user-friendly and easy extraction kits, and usage of DNA/RNA in the marking of new diseases caused by microorganisms. This is expected to raise the DNA/RNA extraction kit market growth during the forecast period.
Notable Developments
In October 2023, PacBio announced the availability of a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis, the PacBio WGS Variant Pipeline. This availability aims to significantly strengthen PacBio’s global sequencing business.
Pacific Biosciences of California, Inc. Price
Pacific Biosciences of California, Inc. price | Pacific Biosciences of California, Inc. Quote
Zacks Rank & Stocks to Consider
PACB carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Acadia Healthcare (ACHC - Free Report) , and Universal Health Services (UHS - Free Report) .
Integer Holdings, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integer Holdings’ shares have rallied 43.5% in the past year against the industry’s 3.7% decline.
Acadia Healthcare, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.4%. ACHC’s long-term earnings are expected to grow at 11.2%.
Acadia’s shares have gained 11.7% in the past six months against the industry’s decline of 5%.
Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated growth rate of 4.4% for 2024. UHS’s earnings surpassed estimates in all the trailing four quarters, delivering an average surprise of 5.47%.
UHS’s shares have gained 1.9% in the past six months against the industry’s 5% decline.